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Abstract 
 
 
This guideline provides background information and practical recommendations for the diagnosis and 
treatment of patients with intracranial and spinal meningiomas. Although meningiomas represent the most 
common intracranial tumors, the level of evidence for recommendations that can be derived from the 
literature is low compared to other tumors. The meningioma task force of the European Association for 
Neuro-Oncology (EANO) assessed the literature available and composed a framework of best possible 
evidence-based recommendations for health professionals. The provisional diagnosis of meningioma is 
mainly made by magnetic resonance imaging. Definitive diagnosis including histological classification, 
grading, and molecular profiling requires a surgical procedure to obtain tumor tissue. In many elderly 
patients, observation is the best therapeutic option. If therapy is deemed necessary, standard treatment is 
gross total surgical resection including the involved dura. As an alternative, radiosurgery can be 
performed for small tumors or fractionated radiotherapy in large or previously treated tumors. Treatment 
concepts combining surgery and radiosurgery or fractionated radiotherapy are evolving allowing 
treatment of the complete tumor volume with low morbidity. Pharmacotherapy for meningiomas has 
remained largely experimental. However, anti-angiogenic drugs, peptide receptor radionuclide therapy 
and increasingly targeted agents are promising candidates for future pharmacological approaches to 
refractory meningiomas across all WHO grades.  
 
Keywords: meningioma, atypical meningioma, anaplastic meningioma, outcome, surgery, radiosurgery, 
radiotherapy, observation, embolization 
Introduction 
Meningiomas are the most common primary intracranial tumors. Most meningiomas are WHO grade I 
lesions whereas a minority are classified as WHO grade II or even grade III lesions, based on local 
invasiveness and cellular features of atypia1. The vast majority of patients can be cured by surgery alone, 
notably patients with WHO grade I tumors at favorable locations. Beyond surgery, various approaches of 
radiotherapy are commonly used to increase local control, particularly if surgery alone seems not to be 
sufficient. In contrast, pharmacotherapy has so far assumed only a minor role in the management of 
meningiomas. Although management may appear to be fairly standardized across the globe, there are 
very few controlled clinical trials, resulting in a situation where standards of care are defined by local 
experience, long-standing traditional procedures, and experience-based practice. However, there are 
numerous situations where more than one approach appears feasible. For example, is there a need for 
intervention in case of incidental meningiomas of unclear growth kinetics? Furthermore, do all 
meningioma-suspect lesions require histological verification of the diagnosis? When is the right time and 
what is the right fractionation approach when radiotherapy is considered? How will medical therapy 
Formatiert:  Keine Aufzählungen oder Nummerierungen
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develop in the future and what is the role of molecular profiling? Defining standards of care and outlining 
answers to some of these difficult questions is the purpose of the present guideline prepared by a task 
force of EANO.  
 
Methods 
 
The authors searched the following databases: the Cochrane Library from January 1990 until May 2016to 
date, the Medline databases from January 1990 to May 2016date, Embase-Ovid (January 1990 to May 
2016date), Cancer Net, Science Citation Index. Sensitive and specific keywords as well as combinations 
of keywords were used. Only publications in English were considered. Publications in any language of the 
countries represented by this EANO task force were considered. Search started May 1st 2015 and 
finished May 16th 2016. The main keywords were meningioma, atypical meningioma, anaplastic 
meningioma, outcome, surgery, radiosurgery, radiotherapy, chemotherapy, observation, embolization, 
Simpson in various combinations.   
The literature available was evaluated and the scientific evidence was sorted into classes I-IV and 
recommendations were rated at level A-C, according to EFNS guidelines2. When sufficient evidence for 
recommendations was not available, the task force offered advice as "good practice point". 
General recommendations 
Recommendations for the diagnostic and therapeutic management of meningioma patients in general, 
including epidemiology and clinical presentation, pathogenesis and risk factors, diagnostic procedures, 
therapeutic decision making, surgical and radiotherapeutic approaches as well as pharmacotherapy are 
summarized in the appendix. WHO grading is displayed in table 13. 
 
 
Specific recommendations 
Recommendations for therapeutic management of meningiomas of WHO grades I-III are outlined in figure 
1. 
Meningioma WHO grade I 
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Meningiomas can be diagnosed by magnetic resonance imaging (MRI) and additional computed 
tomography (CT) in most cases with high probability (figure 2)4. They usually present as solitary round 
tumors, with close contact to the dura mater and strong enhancement after contrast injection. The typical 
appearance of meningioma is isointense on T1 weighted imaging, iso- or hyperintense on FLAIR and with 
high and homogenous enhancement following gadolinium injection. On T2 weighted imaging, the 
meningeal arteries can sometimes be seen as lines of low signal radiating from the center of the tumor 
(typical “sunburst” appearance). Thickening of the dura mater at the perimeter of the tumor (so-called 
dural tail) is displayed by T1 with gadolinium5. CT is valuable for the detection of calcification within the 
tumor, hyperostosis of adjacent bone and intraosseous tumor growth, particularly in skull base 
meningiomas. Conventional cerebral angiography is no longer used forhas no routine role in the 
diagnosis of meningioma, but can be used as an  adjunct to treatment planning in selected casesIt is only 
used for therapy planning in selected cases. Delineation of complex skull base meningiomas may be 
challenging. The expression of somatostatin receptor 2 of meningiomas can be used for discrimination 
from healthy tissue by using peptide ligands such as (68)Ga-Dotatate or (90)Y-Dotatoc as PET tracers6,7. 
Therefore, an improvement of diagnostic management of complex meningiomas can be expected in the 
near future. 
Beyond neurofibromatosis type 2 (NF-2), several genes have been detected as frequently mutated in 
these tumors - for example KLF4 and TRAF7 are oftenalways mutated in secretory meningioma8. It is of 
interest that mutations in these genes are not randomly distributed in meningiomas but form groups with 
typical combinations of mutations and exclusion of other mutations. It is expected that a molecularly 
based classification will be developed and that this classification has the potential to direct individualized 
meningioma-specific therapy (tables 2 and 3). More relevant, pPreliminary findings point to TERT 
mutations, irrespective of WHO grade, being an indicator for more aggressive growth in meningioma9,10. 
Molecular alterations associated with less favorable clinical courses are expected to develop as valuable 
adjuncts to tumor grading for identifying patients at higher risk for meningioma recurrence or progression. 
Additional work to correlate molecular signatures with risk of tumor recurrence and prognosis is needed. 
On the other hand, molecular screening should be able to offer  to more reliably select and predict which 
patients will benefit from adjuvanttargeted therapy for a subset of patients. 
Therapy of meningioma patients needs to be individualized due to the different nature of meningiomas 
and the potential consequences of different treatments to the patients. Manyost asymptomatic, 
incidentally discovered meningiomas can be managed by observation using annual clinical and MRI 
intervals, after an initial observation interval of 6 months11. There is no class I or II evidence to support 
guidelines for observational management of meningiomas, but there are numerous retrospective series 
and several reviews validating this concept12 (evidence level III, recommendation level C). The 
suggestion to treat with surgery rather than observation should be based on a solid indication. Although 
surgery is for the majority of patients the only treatment needed, its long-term sequelae are often 
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overlooked; in a recent study it was shown that forty percent of the patients operated for a meningioma 
experienced cognitive or emotional problems following surgery13. If imaging is highly suggestive of 
meningioma, histological verification is not mandatory; however, it is recommended to exclude rare 
differential diagnoses like metastasis (recommendation level: good practice point). The diagnostic and 
therapeutic role of molecular profiling, which makes the availability of tumor tissue necessary, still needs 
to be established. If therapy is needed because of radiologically confirmed growth or presence of clinical 
symptoms, surgery is the therapy of first choice (evidence level II, recommendation level B). The aim of 
microsurgery is complete tumor removal (gross total resection, GTR) including involved dura 
corresponding to Simpson grade I resection. Extent of resection (EOR) is defined by the Simpson Grade 
(table 4) that relies on the surgeon’s assessment at surgery and is an important prognostic factor for risk 
of tumor recurrence14. Even if the Simpson classification pre-dates modern neuro-imaging and several 
authors see a limited value, it still proved to be valuable for assessing the risk of recurrence in recent 
series12,15. Today, the intraoperative assessment of EOR should be confirmed by postoperative MRI that 
can be performed within 48 h after surgery or after 3 months to avoid artifacts. Preoperative embolisation 
is not generally recommended, however, it may facilitate surgery in selected cases (evidence level IV, 
recommendation level C).  
As an alternative to surgery in elderly patients, for tumors not safely accessible by surgery, or after 
incomplete surgical resection, stereotactic radiosurgery (SRS) can be offered forin case of small tumors. 
A series of 35 retrospective studies showed a 5 year PFS of 86-100 percent after primary SRS16. If the 
tumor volume cannot be treated by a single fraction, fractionated radiotherapy (RT) with 50-55 Gy given 
in 1·8-2.0 Gy per fraction can be applied (evidence level III, recommendation level B). After RT, control 
rates of 75 to 92 % percent are described in various series17-21. When RT is added to subtotal resection 
(STR), control rates and survival similar to GTR are reported22,23. In order to spare tumor-surrounding 
sensitive neurovascular structures and to diminish the well known risk of long term cognitive deterioration, 
intensity modulated radiation therapy (IMRT) and fractionated stereotactic radiotherapy (FSRT) are 
increasingly used, offering similar control rates with conventional RT24-26. In selected cases of small 
meningiomas, SRS allows a single application of 14-16 Gy27-32. The use of planned combination therapies 
consisting of STR or partial resection followed by SRS or RT allows treating the complete tumor whereas 
reducing the risk of treatment30 (evidence level IV, recommendation level C). After therapy, annual MRI 
controls for 5 years are sufficient, followed by bi-annual controls. There are no strong data supporting the 
use of pharmacotherapy in meningiomas of WHO grade I33-36, but this may change soon with the recent 
identification of druggable mutations (see table 3 below)37. Peptide receptor radionuclide therapy (PRRT) 
has shown some effect in small series and will be evaluated in clinical studies38-42. Key recommendations 
regarding therapy are summarized in Table 15. 
 
Meningioma WHO grade II 
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There are no clear radiological criteria to distinguish WHO grade I and grade II meningiomas. Exposure to 
ionizing radiation has been firmly linked to a higher risk for meningiomas and radiation-associated 
meningiomas are more likely to be atypical or malignant and multifocal43-47. The presence of type 2 
neurofibromatosis (NF2) implies a risk of developing malignant or multiple meningiomas, whereas the role 
of NF2 in developing grade II or III meningiomas is not clear. There are increasing dData allowing thefor a 
molecular genetic characterization of atypic and malignant meningiomas accumulate, e.g., TERT 
mutations are associated with higher meningioma grades9,48. 
Surgery is the first choice of treatment and should aim at a Simpson I resection (evidence level III, 
recommendation level B). The diagnosis of WHO grade II meningioma implies an increased risk of 
recurrence requiring shorter control intervals (6 months instead of annual, see below)49. The role of RT as 
an adjuvant therapy is still open. Retrospective series on adjuvant RT after GTR led to differing results 
and prospective data on adjuvant RT after GTR are missing50-56. The ROAM / EORTC 1308 trial 
(ISRCTN71502099) is currently recruiting patients with newly diagnosed atypical meningioma (WHO 
grade II) who have undergone gross total resection (Simpson I-III) and will be randomized between early 
adjuvant radiotherapy (60 Gy in 30 fractions) and observation to determine whether RTradiotherapy 
reduces the risk of or delays tumor recurrence57. For incompletely resected tumors, adjuvant RT (54 to 60 
Gy given in 1·8-2·0 Gy per fraction) should be considered (evidence level III, recommendation level C). In 
cases of progression, RT should be performed if not done following the initial surgery, with or without 
second surgery (evidence level III, recommendation level C). If the diagnosis of a WHO grade II or III is 
made, fractionated radiotherapy is preferred to Sstereotactic radiosurgeryRS techniques, although SRS 
offers similar results for small tumors or tumor remnants58-60. There are no data about PRRT in 
meningioma WHO grade II. In any case, due to lack of definite data regarding adjuvant RTradiotherapy 
and considering the potential long-term effects of RT, discussion with the patient prior to any decision is 
mandatory. The patients should be informed about potential long-term toxicity, which can occur in up to 
53% of cases after RT and a mean follow-up of 12 years23,61. Retrospective studies and small prospective 
studies have evaluated a range of drugs including hydroxyurea, cycophosphamide/adriamycin/vincristine 
chemotherapy, interferon-alpha, megestrol acetate, medroxy-progesterone acetate, octreotide, 
sandostatin LAR, pasireotide LAR, imatinib, erlotinib, gefitinib, vatalanib, sunitinib and bevacizumab in 
WHO grade II and III meningiomas33. PFS-6 rates ranged from 0% to 64% and median OS times from 6 
to 33 months in patients progressing after surgical resection and radiotherapy. The most promising 
results have been reported for bevacizumab, vatalanib and sunitinib, all drugs with anti-angiogenic 
properties33,62-66. These results need to be confirmed in prospective controlled trials, before clinical use of 
these compounds in WHO grade II and III meningiomas can be recommended. An ongoing EORTC 
phase II trial (NCT02234050) explores the efficacy of trabectedin, a tetrahydroisoquinoline that has 
shown promising activity in recurrent WHO grade II and grade III meningiomas67. Altogether, 
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pharmacotherapy canshould be considered upon further progression in meningiomas WHO grade II 
(evidence level IV, recommendation level C). 
 
 
Meningioma WHO grade III 
Anaplastic meningiomas often are more irregularly shaped and display a higher relative cerebral blood 
volume thancompared to WHO grade I and II tumors4. They Meningiomas WHO grade III have a strong 
tendency to recur and may metastasize systemically. There is a high proportion of NF2 mutations in WHO 
grade III meningiomas (table 23), diffuse growth and invasion of the cortex is often described68. Surgical 
resection should be as radical as possible (evidence level III, recommendation level C) and needs to be 
followed by fractionated radiotherapy with at least 54 Gy in 1.8-2 Gy fractions (evidence level III, 
recommendation level B). Current clinical trials address the question of dose: In the RTOG 0539 trial, 
WHO grade II meningiomas are treated by RT with 54 Gy in 30 fractions after GTR, while “high risk 
meningioma” (i.e. WHO grade II recurrent disease, WHO grade II after STR resection and all WHO grade 
III) receive up to 60 Gy (NCT00895622). In the EORTC 22042-26042 trial (NCT00626730), WHO grade II 
and grade III tumors post GTR weare irradiated with 60 Gy in 30 fractions. After STR, 60 Gy plus a 10 Gy 
boost on the remaining tumor volume weare delivered. Results are pending. Follow-up should be 
performed three months after initial therapy, then every 3 or 6 months, depending on initial growth 
kinetics. Pharmacotherapy options remain experimental (evidence level IV, recommendation level C) and 
only little data on the efficacy of antineoplastic drugs in WHO grade III meningiomas are available. No 
clinical trials have focussed on WHO grade III tumors, but small numbers of these neoplasms have been 
included in most studies together with WHO grade II tumors (see above). Consequently, no specific 
recommendations can be made for pharmacotherapy of WHO grade III meningiomas and patients with 
this diagnosis should be enrolled into clinical trials whenever possible. 
Spinal meningiomas 
Surgical resection to remove the tumor and decompress the spinal cord is the therapy of choice for 
patients within spinal meningiomas. The majority of data supports surgical strategies striving for 
completeness of excision. Recurrence rates of spinal meningiomas after surgical resection have been 
reported in the range of 1·3 – 14·7%69-72. There is consensus that incomplete resection is a risk factor for 
recurrence but it is unclear whether Simpson grade I resection achieves better long term outcome than 
Simpson grade II resection69,72-74. Most papers report lower recurrence rates after resection of the 
involved dura but at the cost of a higher complication rate, particularly for meningiomas located 
unfavorably or with severe calcification71. Therefore, Simpson grade I resection should be aimed for in all 
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cases of spinal meningioma with a favorable location, but only if this can be achieved without 
compromising neurological function and if a safe and uncomplicated dural repair is feasible 
(recommendation level: good practice point). For patients with ventrally located meningiomas or with 
calcified dural attachment, excision of the dura should not be the goal – coagulation of the dural 
attachment is sufficient. For the rare cases where (i) surgical resection cannot be performed for any 
reason, (ii) stopping tumor growth is the only aim of treatment and (iii) decompression of the spinal cord 
does not seem necessary, SRS or hypofractionated radiotherapy is an alternative to surgical resection75 
(recommendation level: good practice point). Adjuvant therapy is performed according to the WHO grade 
and resection status as stated above for cranial meningiomas. 
 
Surveillance and follow-up 
Follow-up is needed to prevent future potentially irreversible neurological deficits and to find the optimal 
timing for potential (re-)intervention. There is no robust data on the best follow-up schedule for 
meningiomas, since most retrospective studies do not report on monitoring intervals and since 
prospective studies published so far had variable follow-up protocols, usually tailored to fit the treatment 
visits76,77. Therefore, the following recommendations are based more on expert consensus opinion rather 
than evidence (recommendation level: good practice point).  
Follow-up should be performed clinically by an experienced neurosurgeon or neurooncologist and must 
be accompanied in special cases by additional specialists, e.g., if cranial nerve function is threatened. 
There is considerable variation in follow-up intervals possible depending not only from resection status, 
size and location of the tumor, but also age and the general and neurological status of the patient.  
Our proposed approach forn the management of small, asymptomatic meningiomas is to evaluate the 
dynamics of the tumor with MRI with contrast medium 6 months after initial diagnosis and then annually, 
as long as the patient remains asymptomatic. After five years this interval can be doubled. In patients with 
limited life expectancy due to high age or severe co-morbidities, controls may be omitted if the 
radiological diagnosis of a benign meningioma seems clear.   
Monitoring after initial treatment depends on the EOR and grading of the tumor.  
For WHO I meningiomas resected totally (GTR), the 10-year recurrence rates vary from 20-39%. Studies 
with long follow-up with MRI show that recurrence is more common than previously thought17,22,78. 
Therefore, it is advisable to perform a baseline MRI within 48 hours or after 3 months, in order to assess 
the EOR. Thereafter, we propose annual MRI controls until five years post treatment, then every two 
years. 
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If resection is known to be incomplete, EOR should be documented by early postoperative MRI within 48 
hours. For WHO grade I tumors after STR, the 10-year progression rates vary between 55 and 100% 
suggesting a more vigilant long-term follow-up78,79. For those cases, MRI at 6 and 12 months is 
recommended, then annually.  
The natural history of WHO grade II meningiomas is less clear, since the 2007 WHO criteria changed 
their definition and thus their identification rates. The 5-year recurrence/progression rates may be as high 
as 30% and 40% after GTR and STR, respectively50,51. In these tumors, we suggest an early 
postoperative MRI within 48 hours. Follow up MRI should be done every 6 months for 5 years, then 
annually. 
For WHO grade III meningiomas are aggressive tumors with very poor local control, even after multimodal 
treatment. In the recent studies utilizing the WHO 2007 grading scheme, the 5-year-PFS ranged from 12 
to 57%, even after resection and radiotherapy. Therefore, these tumors have to be followed up very 
closely80. After the initial, early post-treatment MRI, cranial imaging should be routinely done every 6 
months, in rapidly growing cases every 3 months. Key recommendations for follow-up are summarized in 
table 15.  
 
Supportive care and patient management 
 
Most meningiomas are diagnosed in asymptomatic patients11  (Zitat 10). Patients with larger tumors may 
suffer from epilepsy, focal neurologic deficits, vascular complicatons, notably deep venous thrombosis 
and pulmonary embolism, chronically raised intracranial pressure and neurocognitive impairment (Zitate 
7-11 from appendix). Acute and long term treatment of these aspects of meningiomas problems and 
management of the patients affected is are similar to the treatment and management of patients with 
other intracranial tumors such as gliomas81-83. Guidelines for supportive care for these patients have been 
described elsewhere (Soffietti, LGG 2010, Weller HGG, 2014).. 
 
 
Future directions 
 
There is promising progress ion several areas fields inof the diagnosis and therapy of meningiomas. The 
new WHO classification of tumors of the nervous system has refined the subclassification by morphology 
and grade for meningiomas, and recent high-throughput studies have defined novel driver mutations that 
are potentially druggable in subsets of tumors. A major challenge is comprehensive molecular genetic 
characterization of meningiomas of all grades. Genetic profiling will allow for individual estimation of 
prognosis and offer personalized, targeted therapies. Diagnosing the extension of complex meningiomas, 
e.g. pretreated intraosseous skull base tumors, still is challenging. As stated above, PET imaging using 
tracers binding to somatostatin receptor 2 like (68)Ga-Dotatate or (90)Y-Dotatoc is a promising technique 
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that will have an increasing role for delineation of these tumors and therapy planning. This imaging 
technique may also find a place in the could (will?) also influence RANO (response assessment in neuro-
oncology) criteria for meningiomas that are currently under development16d (Zitat Leland Rogers, 2015).. 
Surgical techniques and approaches are more and more refined in terms of individualized risk 
assessment. In case of skull base meningiomas, therapeutic concepts combining subtotal resection and 
radiosurgery will be used more often in order to minimize the treatment risk for the patient. 
MultiInterdisciplinary diagnosis and therapy of meningiomas planned in dedicated is an issue that will be 
increasingly discussed in brain tumor boards should become standard of care. An increasing number of 
prospective studies assessing efficacy and safety of established and novel systemic therapies are on 
their way. These will help to generate higher levels of evidence for futuremeningioma treatment concepts 
and hopefully better outcomes for the minority of tumors that are still difficult to control. 
 
Conclusions 
 
The general levels of evidence for diagnosis and treatment recommendations for patients with of 
meningiomas are low, allowing only recommendations of level B, C and good practice points, despite the 
relative frequency of such tumors. However, there are nNumerous efforts to generate new evidence by 
prospective studies pointing at this currently unmet need in neurooncology are ongoing. The key 
recommendations of the EANO task force which represent the state of knowledge of June 2016, are 
outlined in table 15. 
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Tables 
 
Table 1: 2016 WHO grading for meningiomas 1 
 
WHO Grade Description 
Grade I Low mitotic rate (less than 4 per 10 high power 
fields (HPF) 
Absence of brain invasion 
9 subtypes 
Grade II (atypical) Mitotic rate: 4-19 per HPF, or brain invasion 
or 3 out of 5 specific histologies:  
spontaneous necrosis, sheeting, prominent 
nucleoli, high cellularity, small cellsclear cell or 
chordoid cell types 
Grade III (anaplastic) Mitotic rate: >20 per HPF 
or specific histologies:  
Papillary or rhabdoid meningioma 
 
 
 
Table 2: Mutations in meningiomas 27,28,30 
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AKT1 KLF4 TRAF7 NF2 SMO TERT 
Meningothelial Meningioma WHO grade I 13%  -  8% 22% 16%  -  
Transitional Meningioma WHO grade I 14%  -  5% 33%  -   -  
Fibroblastic Meningioma WHO grade I  -   -   -  70%  -   -  
Psammomatous M. WHO grade I Meningioma WHO grade I  -   -   -  60%  -   -  
Secretory Meningioma WHO grade I  -  100% 100%  -   -   -  
Lymphoplasmacyte-rich Meningioma WHO grade I no data no data no data no data no data no data 
Metaplastic Meningioma WHO grade I 25%  -   -  20%  -   -  
Microcystic Meningioma WHO grade I  -   -   -   -   -   -  
Angiomatous Meningioma WHO grade I 4%  -   -  10%  -   -  
Atypical Meningioma WHO grade II 4%  -  4% 70%  -  6% 
Chordoid Meningioma WHO grade II  -   -   -   -   -   -  
Clear Cell Meningioma WHO grade II  -   -   -  50%  -   -  
Anaplastic Meningioma WHO grade III  -   -   -  70%  -  20% 
Rhabdoid Meningioma WHO grade III no data no data no data no data no data no data 
Papillary Meningioma WHO grade III no data no data no data no data no data no data 
Percentages, values <4% are given as "-" 
 
 
 
 
Table 3: Possible targets for future therapies 
 
Potential drug / drug class Molecular target / biomarker 
AKT inhibitor  AKT1 (p.Glu17Lys) mutation84,85 
27,28 
Hedgehog inhibitor SMO (p.Trp535Leu) mutation 
27,2810,84 
FAK inhibitor NF2/merlin loss86,87 115,116 
Immune checkpoint inhibitor PD1-/PD-L188 117 
VEGF or VEGFR inhibitor VEGF/VEGFR263,89,90 105,118,119 
PI3K inhibitors PI3K91 
Trabectedin DNA, tumor-associated 
macrophages, angiogenesis 10967 
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Table 4: Simpson grades of resection and corresponding EORTC/RTOG definitions of extend of resection 
 
Grade Definition Extent of Resection 
(EOR) 
I Gross total resection of tumor, dural attachment and abnormal bone GTR 
II Gross total resection of tumor, coagulation of dural attachment GTR 
III Gross total resection of tumor without resection or coagulation of 
dural attchments, or extradural extensions (e.g. invaded or 
hyperostotic bone) 
GTR 
IV Partial resection of tumor STR 
V Biopsy of tumor  
 
 
 
 
 
 
 
 
 
Table 5: Key recommendations for the management of meningiomas. 
Diagnosis 
The radiological diagnosis of meningioma should be made by MRI 
Conventional angiography should be restricted to selected cases 
Tissue for future molecular analysis should be stored if available 
Histological verification of meningioma is not mandatory in all cases 
Treatment 
Asymptomatic patients may be managed by observation 
If treatment is indicated in meningioma of any WHO grade, surgery is the first option 
Complete removal (Simpson I) is the primary goal of surgery 
The degree of resection should be confirmed by MRI 
Embolisation should be restricted to selected casess 
Radiosurgery may be the first option in small WHO grade I meningiomas in specific locations 
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Radiosurgery may be the first option in small WHO grade I meningiomas in specific locations 
 
 
Patients with meningioma WHO grade I that cannot be operated on can be treated by fractionated 
radiotherapy or radiosurgery 
Combining subtotal resection and radiosurgery or fractionated radiotherapy should be considered to allow 
comprehensive tumor treatment while reducing the risk of adverse effects from treatment in WHO grade I 
meningiomas 
Patients with incompletely resected meningiomas WHO grade II should receive fractionated radiotherapy 
Pharmacotherapy is experimental in any grade of meningioma and should only be considered if no further 
surgical or radiotherapy options exist. 
Follow-up annuallyyearly 
Follow-up of patients with WHO grade I meningiomas should be done yearly, after 5 years biannually 
Follow-up of WHO grade II meningiomas should be done every 6 months, after 5 years yearly 
Follow-up of WHO grade III meningiomas should be done every three to six months 
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Recommendations for therapeutic management of meningiomas of WHO grades I-III 
 
Figure 2  
 
Meningioma of the right convexity with typical radiological signs 
A : Bone window of the cerebral CT scan in coronal view showing hyperostosis facing the tumor 
B: Cerebral MRI (FLAIR) showing the tumor slightly hyperintense. Note the edema of the parenchyma 
adjacent to the tumor (arrow) 
C: T2 sequences in coronal view showing CSF (small arrows) interposed between tumor and parenchyma 
demonstrating the extra-axial nature of the tumor 
D : T1 weighted MRI after gadolinium injection depicting intense enhancement of the tumor. Note the 
large contact of the tumor with the dura-mater and the thickening of the adjacent dura-mater (arrow).  
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Appendix: 
 
 
Epidemiology and clinical presentation 
Meningiomas have the highest incidence rate among all intracranial and intraspinal tumors. In 
European countries the annual incidence rate of meningiomas is 4·2 per 100·000 individuals1,2. The 
median age at diagnosis is 65 years and incidence increases with age3. The majority of intracranial 
meningiomas are found in the supratentorial compartment, most commonly at the cerebral convexity, 
along the dural venous sinuses, along the falx or intraventricularly. Skull base meningiomas grow at 
the sphenoid wing, olfactory groove, clinoid process or petroclival regions. Additional sites include the 
cerebellopontine angle, the foramen magnum or – less commonly – the optic nerve sheath. Moreover, 
meningiomas represent 25-45% of intradural spinal tumors4. Eighty percent of spinal meningiomas are 
located in the thoracic spine5. Many meningiomas are asymptomatic and diagnosed incidentally. 
There is no clearly defined critical size for the development of symptoms in general, however, 
meningiomas that the general rule is that meningiomas that do not exceed 2.5 cm in diameter, rarely 
cause symptoms within 5 years of being discovered6. An exception can be smaller meningiomas, 
growing close to critical structures (such as the optic nerve) or meningiomas with disproportionally 
large edema or rate of growth. The most common symptoms are epilepsy, or headache for weeks to 
months, or location-specific symptoms or signs such as unilateral weakness, visual field loss, changes 
in personality or speech problems. Meningioma patients exhibithave diminished neurocognitive 
function as compared with healthy controls except for intelligence and visuoconstructive skills7-11. 
Neurocognitive functions in patients with meningiomas in the dominant hemisphere (usually left-side) 
are more compromised than in patients with meningiomas in the non-dominant hemisphere (usually 
right-side). Furthermore, neuro-cognition in patients with skull base meningiomas is worse than in 
patients with convexity meningiomas11. Meningioma patients do not differ from healthy controls with 
respect to anxiety or depression12. In spinal meningiomas, pain, paraparesis and spinal ataxia are the 
typical presenting signs and symptoms and signs, reflecting spinal cord compression5. 
. 
Pathogenesis and risk factors 
Meningiomas are assumed to derive from arachnoid cap cells. The arachnoid mater is the middle part 
of the meninges whose origin is best described as mesenchymal. Meningiomas exhibit epithelial 
features such as multiple intercellular gap junctions and expression of the epithelial membrane 
antigen. They usually occur where meninges are present. However, intraventricular meningioma is an 
important differential diagnosis for tumors of the lateral ventricles. These tumors are believed to arise 
from arachnoid cells entrapped in the choroid plexus during organogenesis. Although rare, distant 
metastases of meningioma to the lung and other sites have been described, not only with anaplastic 
(WHO grade III) meningiomas. Multiplicity of meningioma is observed and clonality has been 
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demonstrated in approximately half of the patients with two spatially separated meningioma 
manifestations, and in all patients with three or more meningioma manifestations13. 
Exposure to ionizing radiation has been firmly linked to a higher risk for meningiomas and radiation-
associated meningiomas are more likely to be atypical or malignant and multifocal14-18. . Type 2 
neurofibromatosis (NF2) is the most common genetic condition associated with an elevated risk for 
developing meningiomas. Patients with NF2 also may be more likely to develop malignant or multiple 
meningiomas. Based on the observations of (i) higher incidences in women of reproductive age, (ii) 
tumor expression of hormone receptors, (iii) an association with breast cancer and (iv) changes in 
meningioma size during pregnancy, the menstrual cycle and menopause, a number of studies have 
sought to link endogenous and exogenous hormone exposure to meningioma growth, without 
significant correlations3,19. 
 
Diagnostic procedures 
 
Imaging  
 
Cerebral magnetic resonance imaging (MRI) and computed tomography (CT) scans, when used in 
combination, allow the diagnosis of intracranial meningioma with high probability in most cases20. MRI 
should comprise the sequences T1, T2 spin echo, T2 gradient echo, fluid-attenuated inversion 
recovery (FLAIR), 3D time-of-flight (TOF) and T1 with gadolinium (see figure 2, main text). When the 
meningioma is located close to a major dural sinus vein, venous MRI angiography should be included 
to verify its patency. CT may be valuable in conjunction with MRI and should comprise bone window 
settings. Typically, meningiomas present as solitary round tumors, with close contact to the dura mater 
and strong enhancement after contrast injection. The typical signal of meningioma is isointense on T1, 
iso- or hyperintense on FLAIR and with high and homogenous enhancement following gadolinium 
injection. On T2, the meningeal arteries can sometimes be seen as lines of low signal radiating from 
the center of the tumor (typical “sunburst” appearance). Thickening of the dura mater at the perimeter 
of the tumor (so-called dural tail) is displayed by T1 with gadolinium21. Extra-axial growth can be 
verified on T2 MRI by CSF interposed between the tumor and the parenchyma22. FLAIR and T2 
sequences depict edema of the surrounding cerebral parenchyma. CT is valuable for the detection of 
calcification of varying degrees within the tumor, hyperostosis of adjacent bone and intraosseous 
tumor growth. Conventional cerebral angiography is no longer used for the diagnosis of meningioma 
and is restricted as an adjunct to selected cases. If cerebral angiography is performed, it shows a 
typical tumoral blush in most cases fed by the middle meningeal artery within the aspect of sunburst. 
Differential diagnoses of meningioma include vestibular schwannoma, if located in the 
cerebellopontine angle, meningeal metastasis, and hemangiopericytoma, if hypervascularity is seen. 
Meningiomas may express somatostatin receptor 2 and can be delineated from healthy tissue by 
positron emission tomography (PET) using peptide ligands such as (68)Ga-Dotatate or (90)Y-Dotatoc 
as PET tracers23,24. 
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Histopathology 
The current world health organization (WHO) classification system recognizes 15 different 
meningioma entities, 9 of which are allotted WHO grade I, 3 WHO grade II and 3 WHO grade III (see 
Tcompare to table 1,  of the main text25body of the guideline paper) (Table 1). Some of these subtypes 
are associated with distinct clinical features: For example, secretory meningioma is frequently 
accompanied by pronounced peritumoral edema, or psammomatous meningioma is predominantly 
seen in the spinal meninges. Over all, the distinction between the 9 WHO grade I meningioma variants 
is of limited clinical relevance. On the other hand, grading of meningioma is of major clinical 
importance, because patients with WHO grade II and grade III meningiomas are considered 
candidates for postsurgical radiotherapy as discussed below. Grading of meningioma depends on 
mitotic rate as well as, presence of brain invasion or presence of some specific histological features. In 
the new WHO classification for central nervous system tumors brain invasion became a criteriumon to 
assignllow a WHO grade II as a single defining feature. Nevertheless, Tthe currently applied 
parameters for defining the borders between the grades are not entirely satisfactory. While patient 
cohorts with WHO grade II meningioma generally exhibit shorter intervals to tumor recurrence, there is 
a considerable number of individual patients with WHO grade I meningiomas WHO grade I with 
unexpectedly early tumor relapse. Conversely, some patients with WHO grade II meningioma, 
especially when a complete resection can be achieved, experience a very prolonged indolent clinical 
course even without adjuvant radiotherapy. 
 
Molecular pathology  
The current dynamics in the analysis of human tumors with massive parallel sequencing have 
provided novel insights into molecular mechanisms involved in the formation and progression of 
meningiomas. Several genes beyond NF2 have been detected as frequently mutated in these tumors - 
for example KLF4 (exclusively) and TRAF7 (commonly) are always mutated in secretory 
meningioma26. NF2 mutations predominate in meningiomas with some spindle cell morphology 
encompassing fibroblastic, transitional and psammomatous meningioma. AKT1 exhibits the E17K 
hotspot mutation in a fraction of meningiomas of basal localization and potentially these tumors have 
actionable targets using specific inhibitors27,28. Another gene with recurrent mutations is SMO29,30. 
These mutations seem to follow a pattern, thus creating molecular subgroups with characteristic 
combinations of mutations. It is of interest that mutations in these genes are not randomly distributed 
in meningiomas but form groups with typical combinations of mutations and exclusion of other 
mutations. It is expected that a future molecularly based classification will be developed and that this 
classification haves the potential to direct individualized meningioma-specific therapy (see Tcompare 
tables 23 and 53, of the main textbody of the guideline) (tables 2 & 4). PMore relevant, preliminary 
findings point to TERT mutations, irrespective of WHO grade, being an indicator for more aggressive 
growth in meningioma31,32. Likewise, PIK3CA mutations are associated with higher meningioma 
grades. Molecular alterations associated with less favorable clinical courses are expected to provide 
guidance develop as valuable adjuncts to tumor grading for identifying patients at higher risk for 
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meningioma recurrence or progression and earlier need for targeted intervention. TIn the future, tumor 
tissue sampling and storage for future molecular testing should become standard of practicewill allow 
for a better understanding of the molecular signatures of the various meningioma types, and for a 
correlation of those signatures with the risk of tumor recurrence. (compare to table 1  of the main body 
of the guideline). Additional work to correlate molecular signatures with tumor recurrence is needed to 
more reliably select and predict which patients will benefit from adjuvant therapy. 
 
Therapeutic strategies 
 
Observation and decision making 
Meningiomas are a common finding on cranial MRI, and are often discovered incidentally33. If a 
meningioma is diagnosed provisionally by neuroimaging, it must be ascertained if (1) the finding has a 
clinical correlate, (2) the symptoms or signs, if any, may be relieved by treating the tumor, and if (3) 
the potential benefits from treatment outweigh the associated risks. If the answer is no to any of these 
three questions, observation may be the best strategy unless there is diagnostic doubt, necessitating 
early verification of the diagnosis. Observation is a preferred strategy in many cases of suspected 
meningioma, especially in small, incidentally discovered tumors. Although class I or II evidence is 
missing in order to support guidelines for observation rather than therapy, tThere is no class I or II 
evidence to support guidelines for observational management of meningiomas, but there are 
numerous retrospective series and several reviews validating this concept6 (evidence level III). The 
most important determinant for symptom development is tumor size at diagnosis. A diameter of 2 cm 
or less is associated with a higher risk of growth, but very few of these tumors become symptomatic 
within a period of 5 years. Another important parameter for symptom development is a growth rate of 
more than 10% per year6. A meta-analysis of 22 retrospective studies  identified calcification and 
absence of peri-tumoural signal change, specifically edema, as factors associated with slower 
meningioma growth. Such tumors may be managed by active surveillance using MRI, and treatment 
should be offered only if they become symptomatic or show growth. 
Due to the different nature of meningiomas and the dissimilarity of meningioma patients, therapy of 
these tumors needs to be individualized. Patients should be counseled about the finding and given 
advice accordingly. Many physicians overlook may underestimate oversee the long-term sequelae of 
brain surgery. VIn the study of van der Vossen et al. reported it was shown that 40% of the patients 
operated for a meningioma experienced cognitive or emotional problems after surgery34.  If a patient 
refuses observation as a management strategy even after thorough information, treatment may be 
justified. If one decides to manage a suspected meningioma by observation alone, it has to be agreed 
who is responsible for patient follow-up. In an ideal setting, this is done by an experienced 
neurosurgeon or neurooncologist. The patient should receive written information about the need for 
follow-up, and the potential consequences of not adhering to the follow-up regimen. Annual MRI scans 
and clinical outpatient consultations are recommended for an initial period assigning the first scan as a 
reference. 
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It is uncertain for how long the follow-up of a meningioma should be continued if there is no sign of 
growth. If a tumor shows significant growth, and in particular if growth leads to new symptoms, 
treatment is usually indicated. In these cases, surgery is advocated if feasible35. In addition or as 
alternatives, various schedules of radiotherapy, radiosurgery or combination therapies may be 
treatment options36. It is strongly recommended that these patients are discussed in a multidisciplinary 
panel of neurosurgeons, radiation oncologists and neuro-oncologists. The patient should be informed 
about the treatment alternatives and the pros and cons of the options should be presented in an 
unbiased way so as to allow the patient an informed decision about the choice of treatment. 
 
Surgery  
Surgery is the treatment of choice for the majority of symptomatic and enlarging meningiomas, serving 
the dual role of relieving symptoms and mass effect and providing tissue for distinguishing histological 
type and WHO grade of malignancy (evidence level II, recommendation level B). Surgical risks should 
be fully discussed with the patients prior to surgery including location-specific risks. There is no 
evidence that prophylactic antiepileptic drugs (AEDs) reduce the incidence of peri- or post-operative 
epilepsy. However, certain locations are more prone to seizures e.g. frontal, temporal, and parietal 
meningiomas have a higher risk than occipital tumors, and convexity and parasagittal/falx 
meningiomas have a higher risk than tumors of the skull base37-39. 
Careful pre-operative planning reduces the risk of post-operative deficits. Attention to venous anatomy 
is a key factor in successful surgery, particularly for meningiomas involving the venous sinuses. 
Whilest it is generally safe to divide the anterior third of the sagittal sinus, inadvertent damage to 
cortical veins and intra-diploic venous drainage can lead to post-operative venous infarction with 
devastating consequences. Image guidance is now routinely used to position the craniotomy and 
allows image fusion of multiple data sets that provide information about critical neurovascular 
structures. Meningiomas that involve the skull base may result in holes in the frontal, sphenoid and 
ethmoid air sinuses - these holes must be sealed off to prevent post-operative cerebrospinal fluid 
leaks. Care should also be taken when resecting meningiomas near to the optic apparatus so as not 
to disrupt blood supply which could result in visual loss. Intra-operative neurophysiological monitoring, 
e.g. facial nerve and brainstem-evoked potentials, may help to minimize neurological deficits. 
The general principles of meningioma surgery are dividing the tumor from its blood supply and internal 
debulking followed by peripheral dissection. The aim is gross total resection including involved dura 
and bone, but this is determined by tumor location and size. If tumor location does not permit complete 
resection without significant neurological deficit for the patient, maximum safe resection has to be 
defined as primary surgical goal. If tumor remnants need to be left, these can be monitored with MRI 
or treated with post-operative conformal or stereotactic fractionated radiotherapy or radiosurgery, 
depending on location, size and proximity to critical structures, e.g., cavernous sinus. 
Extent of resection (EOR) as iis defined by the Simpson Grade (see table 4, main text) (table 3) that 
relies on the surgeon’s assessment at surgery and is an important prognostic factor for risk of tumor 
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recurrence40. Even thoughif the relevanceactuality and prognotstic strength of the Simpson 
classification has been questionedpre-dates modern neuro-imaging and several authors see a limited 
value41, a recent series shows that the the Simpson classificationit still proved to be valuablehas a role  
forin assessing the risk of recurrence in recent series40. Today, the intraoperative assessment of 
Simpson grade should be confirmed by postoperative MRI that can be performed within 48 h after 
surgery or after 3 months to avoid artifacts. In case of incomplete resection or suspected WHO grade 
II or III meningioma, early MRI within 48 hours should be performed to plan further therapy. In modern 
neurosurgery, the potential benefit of radical surgical resection must be balanced against the risks of 
complications and causing neurological deficit. In WHO grade I meningioma, defining EOR as either 
gross total resection ,resection, i.e. no residual solid tumor, or subtotal resection (STR) is an equally 
good prognostic factor for tumor recurrence41.  Several clinical research consortia including the 
European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy 
Oncology Group (RTOG) have adopted these definitions for use in prospective clinical trials42. 
Regarding spinal meningiomas, the majority of data supports surgical strategies striving for 
completeness of excision. Recurrence rates of spinal meningiomas after surgical resection have been 
reported in the range of 1·3 – 14·7%43-46. There is consensus that incomplete resection is a risk factor 
for recurrence but it is unclear whether Simpson grade I resection achieves better long-term outcome 
than Simpson grade II resection43,46-48. Most papers report lower recurrence rates after resection of the 
involved dura but at the cost of a higher complication rate, particularly for meningiomas located 
unfavorably or with prominentsevere calcification45. Therefore, Simpson grade I resection should be 
aimed for in all cases of spinal meningioma with a favorable location, but only if this can be achieved 
without compromising neurological function and if a safe and uncomplicated dural repair is feasible. 
For patients with ventrally located meningiomas or with calcified dural attachment, excision of the dura 
should not be the goal – coagulation of the dural attachment is sufficient.  
In conclusionany case, the decision for surgery versus observation should balance the benefit of 
surgery, i.e. tumor removal versus potential also take into account the long-term sequelae of the 
surgical treatment. Up to 40% of meningioma patients after surgery experience cognitive or emotional 
problems such as cognitive complains, anxiety and depression34.  
 
Radiotherapy 
External beam radiation therapy (RT) has been used extensively in patients with meningioma for the 
following indications: (i) in tumor locations not amenable to surgery, (ii) in tumors that are not 
completely resected, (iii) in atypical and malignant tumors and (iv) in recurrent tumors. No randomized 
or prospectively controlled studies have evaluated the survival and tumor control and survival after 
conventional RT. Nevertheless, retrospective studies of patients with residual or recurrent WHO grade 
I meningiomas report a local control rate of 75-90% at 10 years49-53. In a series of 82 patients with skull 
base meningiomas treated with conventional RT, Nutting et al. reported 5-year and 10-year local 
tumor control rates of 92% and 83%, respectively52. In another series of 101 patients treated with 3-
dimensional (3D) conformal RT, Mendenhall et al. reported a local control of 95% at 5 years and 92% 
Kommentiert [G1]: Stimmt das Zitat 12? Es hat zu tun mit 
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at 10 and 15 years, respectively, and cause-specific survival rates of 97% and 92%, respectively51. 
The reported control and survival after subtotal resection and RT are similar to those observed after 
complete resection, and better than that achieved with incomplete resection alone54,55 (evidence level 
III, recommendation level B). 
Large skull base meningiomas may present a therapeutic challenge. Also in these tumors, RT has 
been suggested as an effective treatment. A 5-year tumor control in the range of 90 to 97% has been 
reported for skull base meningiomas up to 5 cm in greatest dimension53,56,57; however, meningiomas 
larger than 5 cm in size seem to be associated with worse local control58,59. There is little evidence that 
timing of RT is important, as local control and survival rates are similar whether the treatment is given 
as a part of the primary treatment or at the time of recurrence51-53,60. In most series, the administered 
dose ranged between 50 and 57 Gy delivered in daily fractions of 1.8-2 Gy. The tumor control rates 
were similar for doses of 50-55 Gy or > 55 Gy51,53,57,59-64. Doses below 50 Gy were associated with 
higher, mostly local recurrence rates51,60.  
There is a significant long-term risk of cognitive impairment after brain tumor radiotherapyRT to the 
brain65. In order to spare tumor-surrounding sensitive neurovascular structures, technical advances 
have enabled administration of fractionated RT by the use of intensity modulated radiation therapy 
(IMRT) and fractionated stereotactic radiotherapy (FSRT). FSRT has shown to improve symptoms 
within 1-3 months after treatment66. Using FSRT with median doses of 57 Gy, Milker-Zabel et al. 
reported a 10-year local control of 89% in 317 patients with either skull base or intracranial 
meningiomas, and similar tumor control rates have been observed in other series of FSRT59,62,67,68. 
Combs et al. evaluated the outcomes of 506 patients with skull base meningiomas who received 
FSRT (n =376) or IMRT (n=131), reporting a similar local control of 91% at 10 years for patients with 
WHO grade I meningiomas67. Thus, both techniques are probably effective as primary and salvage 
treatment for meningiomas, with a local control at 5 and 10 years similar to that reported with 
conformal RT. Particle therapies like proton and carbon ion irradiation allow a high dose deposition on 
the tumor providing very low doses to the surrounding adjacent tissues via the “Bragg Peak”. 
Irradiation and re-irradiation of meningioma using protons or carbon ions as stand-alone therapies or 
in combination with photon therapy have been reported to be well tolerated and to allow dose 
escalation, particularly in WHO grade II and III meningioma, showing good local control rates61,69-71. 
There is some evidence that dose escalation >60 Gy or even 65 Gy could lead to a better cause 
specific survival in patients with atypical and malignant meningioma69. However, proton therapy 
remainshas yet to be evaluated in prospective clinical trials. 
The role of RT for WHO grade II meningiomas, specifically its timing, remains unclear. In a series of 
83 patients of whom 66% had undergone GTR, Park et al. reported a 5-year tumor control of 59% 
versus 44% with and without postoperative RT, respectively72. Improved progression-free survival 
rates after postoperative RT have been observed in comparative retrospective series73-75. On the 
contrary, other studies showed no advantages in terms of progression-free survival for adjuvant RT76-
78. For WHO grade III meningiomas, postoperative RT using doses of 55-60 Gy in 1.8-2.0 Gy daily 
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fractions is an established treatment by consensus. There is a trend toward longer survival for patients 
who had received adjuvant RT after surgery compared to those treated with surgery alone79,80. 
Current clinical trials address the question of dose: In the RTOG 0539 trial, "WHO grade II 
meningiomas intermediate risk" meningiomas (i.e. recurrent WHO grade I or WHO grade II after GTR) 
are treated by RT with 54 Gy in 30 fractions after GTR, while “high risk meningioma” (i.e. WHO grade 
II recurrent disease, WHO grade II after STR and all WHO grade III) receive up to 60 Gy 
(NCT00895622). The ongoing EORTC 22042–26042 trial evaluateds the efficacy of high-dose 
radiotherapy (RT) in atypical/malignant meningioma (NCT00626730). In this phase II study, In the 
EORTC 22042-26042 trial, WHO grade II and grade III tumors post GTR are irradiated with 60 Gy in 
30 fractions. After STR, 60 Gy plus a 10 Gy boost on the remaining tumor volume are delivered. The 
ROAM / EORTC 1308 trial (ISRCTN71502099) is currently recruiting patients is a multicenter, phase 
III, randomized controlled trial that is currently recruiting patients   and will answer the question 
whether early adjuvant RT reduces recurrence compared with active monitoring in patients, who have 
undergone GTR of newly diagnosed atypical meningioma.  AM, does early adjuvant radiotherapy 
reduce recurrence compared with active monitoring?with newly diagnosed atypical meningioma (WHO 
grade II) who have undergone gross total resection (Simpson I-III) and will randomize between early 
adjuvant radiotherapy (60 Gy in 30 fractions) and observation to determine whether radiotherapy 
reduces the risk of tumor recurrence81. 
Radiosurgery  
In cases that are associated with increased surgical risk, radiosurgery by gamma knife, cyber knife or 
other types of linear accelerator can be regarded as an effective alternative for radiologically 
diagnosed meningiomas. The dose used for radiosurgery in meningiomas is highly dependent upon 
the technique applied, the prescribed isodose, the proximity of neurovascular structures at risk, as well 
as the size and configuration of the tumor. Generally, a single coverage dose of 14 to 16 Gy is 
recommended 77. Besides direct cellular and toxic effects on tumor cells, the impact of a single high 
dose irradiation on nutritive microvessels seems to be relevant82. Radiosurgery may be indicated – 
even as first therapeutic option - in particular situations like tumor location in the cavernous sinus or 
the clivus, multiple meningiomas, partially resected tumors, recurrent meningioma, or in cases where 
comorbidities preclude open surgery. In these situations, radiosurgery can be used as an exclusive 
therapeutic option based on neuroimaging alone or as part of a combination therapy together with a 
planned partial surgical resection. A series of 35 retrospective studies showed 5 year progression free 
survival (PFS) of 86-100 percent after primary radiosurgery83. A study analyzing the outcome of 79 
patients with cavernous sinus meningiomas treated by radiosurgery alone revealed a tumor control 
rate of 89.8% at 10 years84. A similar excellent clinical outcome and low toxicity have been reported in 
a few series with the use of multi-session radiosurgery at doses of 18-25 Gy delivered in 2 to 5 daily 
fractions in patients with meningiomas larger than 2·5-3·0 cm in size and/or situated close to critical 
structures85,86. Although promising, the limited numbers of patients and follow-up time does not allow 
drawing definitive conclusions on the use of hypofractionated regimens in routine clinical practice as 
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an alternative to conventionally fractionated RTradiotherapy. Petroclival meningiomas or sphenoid 
meningiomas are potential candidates for treatment strategies combining surgery and 
radiosurgery49,87. In the latter tumors, combination therapy allows surgical decompression of the optic 
apparatus and irradiation of tumor remnants in the cavernous sinus. Radiosurgery has also been 
selected for treatment of recurrent atypical meningiomas. The overall survival of these patients was 
87% after 5 years and 75% after 10 years88. Multiple meningiomas and intracranial meningiomatosis 
might be an indication for radiosurgery, if there is no more treatment potential for surgery or 
fractionated RTradiotherapy89.  
There are no prospective randomized data comparing fractionated RT and radiosurgery. The control 
rates 5 and 10 years after RT or radiosurgery for WHO grade I meningiomas are very similar. Ten10 
year PFS after RT using FSRT or IMRT was reported as 91% whereas 83 to 97% are documented for 
radiosurgery67,90. Radiosurgery allows treatment of a circumscribed volume using a single dose, 
therefore achieving a high patient comfort. On the other hand, the use of radiosurgery is limited to 
small and non-infiltrative disease and locations distant from sensitive critical structures such as visual 
pathways because of the radiosensitivity of late reacting normal tissue to dose per fraction. In these 
indications, fractionated RT that sometimes can be performed using the same machines is preferred to 
radiosurgery. In case of infiltrative meningioma growth or WHO grade II or III meningiomas, which 
have a high recurrence rate, fractionated techniques seem superior91. 
Any decision for RT should take into account the long-term side effects of RTradiation therapy, and 
these should be discussed with the patient. In the literature, Tthe incidence of treatment toxicity ranges 
from 3.,4% to 16.,7%. Neurocognitive impairment has been described in 53% of cases65   Although 
blindness due to involvement of the neuro-optic structures into the treatment field hais been reported 
to occurring in 5% of patients, newer studies show this risk to be significantly lower, probably due to 
the modern treatment techniques and doses92,93. If the pituitary gland receives irradiation, there may 
be changes in hormonal levels; although hypogonadism is relatively rare (up to 6%), hypopituitarism is 
reported in up to 50% of cases, and early involvement of the endocrinologist is advisable92. 
Peptide Receptor Radionuclide Therapy (PRRT) 
Some meningiomas show prominent expression of somatostatin receptors and peptide receptor 
radionuclide therapy (PRRT) using radiopeptides targeting somatostatin receptors such as 90Y-
DOTATOC ([90Y-DOTA0, Tyr3]-octreotide), 177Lu-DOTATATE ([177Lu-DOTA0,Tyr3]-octreotate) and 
111ln-Pentreotide has been evaluated in small series or singular cases of somatostatin receptor-
positive meningiomas. PRRT was well tolerated and some disease stabilizations and few partial 
responses were reported. However, the available evidence is anecdotal and well designed studies are 
needed to evaluate the role of PRRT in meningiomas. In the meantime, PRRT should preferentially be 
offered in the framework of clinical studies94-98. 
Embolization 
Formatiert: Abstand Nach:  18 Pt.
Kommentiert [RG2]: Reference Douw fehlt immer noch!!! 
10 
 
Preoperative embolisation of meningiomas aims ato reducinge blood loss during surgical resection99-
101. Unlike some hypervascular tumors, such as hemangioblastomas, for which embolisation is almost 
always carried out prior to surgery, Indications for embolisation of meningiomas vary substantially 
depending on the neurosurgical team102. There is no controlled study that shows better clinical 
outcomes of surgery if it has been preceded by pre-operative embolisation. Consequently, there is no 
general indication for embolisation of meningioma; individual indications are assessed on a case by 
case basis by each team. The principle is to first and foremost occlude the afferent arteries that cannot 
be reached by the surgeon when accessing the tumor. This is performed by free flow particle injection 
or coil embolisation within 24 hours of planned surgery. Complications may arise when the 
neuroradiologist tries to distally guide the embolus into the capillary bed of the tumor. This can result in 
tumor hemorrhage, erratic embolisation through anastomosis or cranial nerves palsy103,104. Four 
different anatomical scenarios can be discussed: (i) In the very common convexity meningiomas, there 
is infrequently an indication for preoperative embolisation. If an embolisation is indicated, 100 to 300 
µm particles are injected into the middle meningeal artery. These small particles allow a more distal 
penetration into the tumor bed. This results in a more substantial necrotic effect on the tumor, but their 
use also entails a higher risk of intra-tumoral hemorrhage103,105. A controlled study indicated that 
preoperative embolisation resulted in a significant reduction of perioperative blood loss99. Reported 
complications are tumor hemorrhage and ischemia due to erratic movement of the emboli. The 
incidence of complications varies from 0 to 9 %. (ii) Olfactory meningiomas are generally vascularized 
by ethmoidal arteries. Since these are branches of the ophthalmic artery implicating a risk of 
jeopardizing vision by embolisation, these tumors should never be embolized. (iii) Meningiomas of the 
cavernous sinus can be subjected to preoperative embolisation. However, the afferent arteries are 
small-sized dural arteries emanating from the carotid siphon which, aside from rare cases, are not 
amenable to selective catherization. Therefore, if an indication for embolisation of a cavernous sinus 
meningioma is made in very rare cases due to a lack of therapeutic alternatives, the internal carotid 
artery would needs to be occluded after testing patency of the Circle of Willis. (iv) Petroclival 
meningiomas can be embolised via the meningeal trunk of the ascending pharyngeal artery. This 
artery cannot be controlled by the neurosurgicallyeon during lateral approaches to the clivus, the 
petrous bone or the cerebellopontine angle106. 
 
Pharmacotherapy and experimental therapies 
 
Pharmacotherapy of meningiomas is typically considered in the following main patient populations: (i) 
patients with recurrent or progressive meningiomas of all tumor grades in whom surgical resection or 
radiotherapy RT are no longer feasible, and (ii) patients with metastatic meningioma. Principally, 
systemic therapy appears to be able to inhibit meningioma growth to some extent107. A variety of drugs 
have been studied in meningiomas. However, the interpretation of most of the available studies is 
limited by several factors, in particular small patient numbers, the retrospective design of most studies, 
the heterogeneity of patient populations with regard to tumor type and prior therapies, the lack of 
comparator treatment arms or reliable historical benchmark activity parameters and the lack of 
standardized response criteria. Thus, pharmacotherapy of meningioma has so far an unclear benefit 
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and has to be considered experimental. Overall, inclusion of patients with meningiomas in clinical trials 
evaluating novel treatment approaches is recommended. Depending on ongoing molecular 
classification of meningiomas, targeted therapies are evolving (seecompare Ttable 53, of the main 
textbody of the guideline) (table 4). 
 
WHO grade I meningiomas 
Hydroxyurea, temozolomide, irinotecan, interferon-alpha, sandostatin LAR, pasireotide LAR, imatinib, 
erlotinib and gefitinib have been studied in retrospective and single-arm phase II studies in WHO 
grade I meningiomas that have failed surgical resection and radiotherapy108,109. Mifepristone was 
studied in a randomized phase III trial but failed to show any advantage over placebo110. The PFS-6 
rates in these studies ranged from 0% to 67%, while median OS times were only inconsistently 
reported and ranged from 7 to 13 months108. The lack of clear data on the natural course and the 
uncontrolled character of these studies preclude definite conclusions. Based on the available data, 
none of the evaluated drugs showed clear signs of clinically relevant activity sufficient to recommend 
them for standard practive clinical use. Notably tTemozolomide is not active in meningioma111. 
 
WHO grade II and III meningiomas 
Retrospective studies and small prospective studies have evaluated a range of drugs including 
hydroxyurea, cycophosphamide/adriamycin/vincristine chemotherapy, interferon-alpha, megestrol 
acetate, medroxy-progesterone acetate, octreotide, sandostatin LAR, pasireotide LAR, imatinib, 
erlotinib, gefitinib, vatalanib, sunitinib and bavacizumab in patients with WHO grade II and III 
meningiomas108. PFS-6 rates ranged from 0% to 64% and median OS times from 6 to 33 months in 
patients progressing after surgical resection and radiotherapy108. The most promising results have 
been reported for bevacizumab, vatalanib and sunitinib, all drugs with anti-angiogenic 
properties107,108,112-114. These results need to be confirmed in prospective controlled trials, before 
clinical use of these compounds in patients with WHO grade II and III meningiomas can be 
recommended. An ongoing EORTC phase II trial (NCT02234050) explores the efficacy of trabectedin, 
a tetrahydroisoquinoline that has shown promising activity in recurrent WHO grade II and grade III 
meningiomas115. 
 
 
Surveillance and follow up of meningiomas 
 
There is only litte no robust data available on the best follow-up schedule for meningiomas, since most 
retrospective studies do not report on monitoring intervals and since prospective studies published so 
far had variable follow-up protocols, usually tailored to fit the treatment visits. Therefore, the following 
recommendations are based more on expert consensus opinion rather than evidence. 
An experienced neurosurgeon or neurooncologist should be in charge for the follow up.Follow up 
should be performed clinically by an experienced neurosurgeon or neurooncologist and. This must be 
accompanied in special cases by additional specialists, e.g., an ophthalmologist should closely 
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monitor the visual status in case of a tuberculum sellae meningiomas or an audiologist should monitor 
the hearing level in case of a cerebellropontine angle tumor. The re is a considerable variation in 
follow up intervals possible which should depend not only from resection status, size and location of 
the tumor, but also age and the general and neurological status of the patient.  
Our proposed approach on the management ofFor small, asymptomatic meningiomas we suggest is to 
evaluate the dynamics of the tumor with MRI with contrast medium 6 months after initial diagnosis and 
then annually, as long as the patient remains asymptomatic. After five years this interval can be 
doubled. In patients where the identification of a tumor progression has no clinical relevance or 
consequense, e.g. patients with limited life expectancy due to high age or severe co-morbidities, 
controls may be omitted. if the radiological diagnosis of a benign meningioma seems clear.   
 
Monitoring after initial treatment should depend on the extent of resection and grading of the tumor.  
Even forFor WHO I meningiomas resected totally, the 10-year recurrence rate in the literature is 
reported up tos vary from 20- 39% and . Studies with long follow-up with MRI show that recurrence 
ithus more common than previously thought. Therefore, it is advisable to perform a baseline MRI 
within 48 hours or after 3 months, in order to assess the EORThe EOR should be controlled with a 
baseline MRI either within 48 hours after the operation or after 3 months. Thereafter, we propose 
suggest annual MRI controls until for the first five years post treatment, then every two yearsand then 
biannually. 
If resection is known to be incomplete, EOR should be documented by early postoperative MRI within 
48 hours. For WHO grade I tumors after STR, the 10-year progression rates vary between 55 and 
100% suggesting a more vigilant long-term follow-up116,117. For those cases, MRI at 6 and 12 months 
is recommended, then annually.  
The course of patients withnatural history of WHO grade II meningiomas might vary within a wide 
rangeis less clear, since the 2007 WHO criteria changed their definition and thus their identification 
rates. The 5-year recurrence/progression rates are reported may be as high as 30% and 40% after 
GTR and STR, respectively73,76.To monitor these tumors In these tumors, we suggest an early 
postoperative MRI within 48 hours as a basis for further observation. Follow- up MRI should be done 
every 6 months for 5 years, then annually. 
WHO grade III meningiomas are aggressive tumors with very poor local control, even after multimodal 
treatment. In the recent studies utilizing the WHO 2007 grading scheme, the 5-year-PFS ranged from 
12 to 57%, even after resection and RTradiotherapy. Therefore,For these tumors have to be followed 
up very close follow-up is to be recommendedly118. After the initial, early post-treatment MRI, cranial 
imaging should be routinely done every 6 months, in rapidly growing cases every 3 months.  
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Appendix: 
 
Epidemiology and clinical presentation 
Meningiomas have the highest incidence rate among all intracranial and intraspinal tumors. In 
European countries the annual incidence rate of meningiomas is 4.·2 per 100·000 individuals1,2. The 
median age at diagnosis is 65 years and incidence increases with age3. The majority of intracranial 
meningiomas are found in the supratentorial compartment, most commonly at the cerebral convexity, 
along the dural venous sinuses, along the falx or intraventricularly. Skull base meningiomas grow at 
the sphenoid wing, olfactory groove, clinoid process or petroclival regions. Additional sites include the 
cerebellopontine angle, the foramen magnum or – less commonly – the optic nerve sheath. Moreover, 
meningiomas represent 25-45% of intradural spinal tumors4. Eighty percent of spinal meningiomas are 
located in the thoracic spine5. Many meningiomas are asymptomatic and diagnosed incidentally. 
There is no clearly defined critical size for the development of symptoms in general, however, 
meningiomas that do not exceed 2.5 cm in diameter rarely cause symptoms within 5 years of being 
discovered6. An exception can be smaller meningiomas, growing close to critical structures (such as 
the optic nerve) or meningiomas with disproportionally large edema or rate of growth. The most 
common symptoms are epilepsy, or headache for weeks to months, or location-specific symptoms or 
signs such as unilateral weakness, visual field loss, changes in personality or speech problems. 
Meningioma patients exhibit diminished neurocognitive function as compared with healthy controls 
except for intelligence and visuoconstructive skills7-11. Neurocognitive functions in patients with 
meningiomas in the dominant hemisphere (usually left-side) are more compromised than in patients 
with meningiomas in the non-dominant hemisphere (usually right-side). Furthermore, neuro-cognition 
in patients with skull base meningiomas is worse than in patients with convexity meningiomas11. 
Meningioma patients do not differ from healthy controls with respect to anxiety or depression12. In 
spinal meningiomas, pain, paraparesis and spinal ataxia are the typical presenting symptoms and 
signs, reflecting spinal cord compression5. 
 
Pathogenesis and risk factors 
Meningiomas are assumed to derive from arachnoid cap cells. The arachnoid mater is the middle part 
of the meninges whose origin is best described as mesenchymal. Meningiomas exhibit epithelial 
features such as multiple intercellular gap junctions and expression of the epithelial membrane 
antigen. They usually occur where meninges are present. However, intraventricular meningioma is an 
important differential diagnosis for tumors of the lateral ventricles. These tumors are believed to arise 
from arachnoid cells entrapped in the choroid plexus during organogenesis. Although rare, distant 
metastases of meningioma to lung and other sites have been described, not only with anaplastic 
(WHO grade III) meningiomas. Multiplicity of meningioma is observed and clonality has been 
demonstrated in approximately half of the patients with two spatially separated meningioma 
manifestations, and in all patients with three or more meningioma manifestations13. 
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Exposure to ionizing radiation has been firmly linked to a higher risk for meningiomas and radiation-
associated meningiomas are more likely to be atypical or malignant and multifocal14-18. Based on the 
observations of (i) higher incidences in women of reproductive age, (ii) tumor expression of hormone 
receptors, (iii) an association with breast cancer and (iv) changes in meningioma size during 
pregnancy, the menstrual cycle and menopause, a number of studies have sought to link endogenous 
and exogenous hormone exposure to meningioma growth, without significant correlations3,19. 
 
Diagnostic procedures 
 
Imaging  
 
Cerebral magnetic resonance imaging (MRI) and computed tomography (CT) scans, when used in 
combination, allow the diagnosis of intracranial meningiomain most cases20. MRI should comprise the 
sequences T1, T2 spin echo, T2 gradient echo, fluid-attenuated inversion recovery (FLAIR), 3D time-
of-flight (TOF) and T1 with gadolinium (see figure 2, main text). When the meningioma is located close 
to a major dural sinus vein, venous MRI angiography should be included to verify its patency. CT may 
be valuable in conjunction with MRI and should comprise bone window settings. Typically, 
meningiomas present as solitary round tumors, with close contact to the dura mater and strong 
enhancement after contrast injection. The typical signal of meningioma is isointense on T1, iso- or 
hyperintense on FLAIR and with high and homogenous enhancement following gadolinium injection. 
On T2, the meningeal arteries can sometimes be seen as lines of low signal radiating from the center 
of the tumor (typical “sunburst” appearance). Thickening of the dura mater at the perimeter of the 
tumor (dural tail) is displayed by T1 with gadolinium21. Extra-axial growth can be verified on T2 MRI by 
CSF interposed between the tumor and the parenchyma22. FLAIR and T2 sequences depict edema of 
the surrounding cerebral parenchyma. CT is valuable for the detection of calcification of varying 
degrees within the tumor, hyperostosis of adjacent bone and intraosseous tumor growth. Conventional 
cerebral angiography is no longer used for the diagnosis of meningioma and is restricted as an adjunct 
to selected cases. If cerebral angiography is performed, it shows a typical tumoral blush in most cases 
fed by the middle meningeal artery within the aspect of sunburst. Differential diagnoses of meningioma 
include vestibular schwannoma, if located in the cerebellopontine angle, meningeal metastasis, and 
hemangiopericytoma, if hypervascularity is seen. Meningiomas may express somatostatin receptor 2 
and can be delineated from healthy tissue by positron emission tomography (PET) using peptide 
ligands tracers such as (68)Ga-Dotatate or (90)Y-Dotatoc23,24. 
 
 
Histopathology 
The current world health organization (WHO) classification system recognizes 15 different 
meningioma entities, 9 of which are allotted WHO grade I, 3 WHO grade II and 3 WHO grade III (see 
Table 1, main text25. Some of these subtypes are associated with distinct clinical features: For 
example, secretory meningioma is frequently accompanied by pronounced peritumoral edema, or 
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psammomatous meningioma is predominantly seen in the spinal meninges. Over all, the distinction 
between the 9 WHO grade I meningioma variants is of limited clinical relevance. On the other hand, 
grading of meningioma is of major clinical importance, because patients with WHO grade II and grade 
III meningiomas are considered candidates for postsurgical radiotherapy as discussed below. Grading 
of meningioma depends on mitotic rate as well as presence of brain invasion or specific histological 
features. In the new WHO classification for central nervous system tumors brain invasion became a 
criterium to assign a WHO grade II as a single defining feature. Nevertheless, the currently applied 
parameters for defining the borders between the grades are not entirely satisfactory. While patient 
cohorts with WHO grade II meningioma generally exhibit shorter intervals to tumor recurrence, there is 
a considerable number of individual patients with WHO grade I meningiomas with unexpectedly early 
tumor relapse. Conversely, some patients with WHO grade II meningioma, especially when a 
complete resection can be achieved, experience a long indolent clinical course even without adjuvant 
radiotherapy. 
 
Molecular pathology  
The current dynamics in the analysis of human tumors with massive parallel sequencing have 
provided novel insights into molecular mechanisms involved in the formation and progression of 
meningiomas. Several genes beyond NF2 have been detected as frequently mutated in these tumors - 
for example KLF4 (exclusively) and TRAF7 (commonly) are mutated in secretory meningioma26. NF2 
mutations predominate in meningiomas with some spindle cell morphology encompassing fibroblastic, 
transitional and psammomatous meningioma. AKT1 exhibits the E17K hotspot mutation in a fraction of 
meningiomas of basal localization and potentially these tumors have actionable targets using specific 
inhibitors27,28. Another gene with recurrent mutations is SMO29,30. These mutations seem to follow a 
pattern, thus creating molecular subgroups with characteristic combinations of mutations. It is 
expected that a future molecularly based classification will have the potential to direct individualized 
meningioma-specific therapy (see tTables 2 and 3, main text). Preliminary findings point to TERT 
mutations, irrespective of WHO grade, being an indicator for more aggressive growth in 
meningioma31,32. Molecular alterations associated with less favorable clinical courses are expected to 
provide guidance for identifying patients at higher risk for meningioma recurrence or progression and 
earlier need for targeted intervention. Tumor tissue sampling and storage for future molecular testing 
should become standard of practice. . 
 
Therapeutic strategies 
 
Observation and decision making 
Meningiomas are a common finding on cranial MRI, and are often discovered incidentally33. If a 
meningioma is diagnosed provisionally by neuroimaging, it must be ascertained if (1) the finding has a 
clinical correlate, (2) symptoms or signs, if any, may be relieved by treating the tumor, and if (3) the 
potential benefits from treatment outweigh the associated risks. If the answer is no to any of these 
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three questions, observation may be the best strategy unless there is diagnostic doubt, necessitating 
early verification of the diagnosis. Observation is a preferred strategy in many cases of suspected 
meningioma, especially in small, incidentally discovered tumors. Although class I or II evidence is 
missing in order to support guidelines for observation rather than therapy, there are numerous 
retrospective series and several reviews validating this concept6 (evidence level III). The most 
important determinant for symptom development is tumor size at diagnosis. A diameter of 2 cm or less 
is associated with a higher risk of growth, but very few of these tumors become symptomatic within a 
period of 5 years. Another important parameter for symptom development is a growth rate of more 
than 10% per year6. A meta-analysis of 22 retrospective studies identified calcification and absence of 
peri-tumoural signal change, specifically edema, as factors associated with slower meningioma 
growth. Such tumors may be managed by active surveillance using MRI, and treatment should be 
offered only if they become symptomatic or show growth. 
Due to the different nature of meningiomas and the dissimilarity of meningioma patients, therapy of 
these tumors needs to be individualized. Patients should be counseled about the finding and given 
advice accordingly. Many physicians  may underestimate the long-term sequelae of brain surgery. Van 
der Vossen et al. reported that 40% of the patients operated for a meningioma experienced cognitive 
or emotional problems after surgery34. If a patient refuses observation as a management strategy 
treatment may be justified. If one decides to manage a suspected meningioma by observation alone, it 
has to be agreed who is responsible for patient follow-up. In an ideal setting, this is done by an 
experienced neurosurgeon or neurooncologist. The patient should receive written information about 
the need for follow-up, and the potential consequences of not adhering to the follow-up regimen. 
Annual MRI scans and clinical outpatient consultations are recommended for an initial period 
assigning the first scan as a reference. 
It is uncertain for how long the follow-up of a meningioma should be continued if there is no sign of 
growth. If a tumor shows significant growth, and in particular if growth leads to new symptoms, 
treatment is usually indicated. In these cases, surgery is advocated if feasible35. In addition or as 
alternatives, various schedules of radiotherapy, radiosurgery or combination therapies may be 
treatment options36. It is strongly recommended that these patients are discussed in a multidisciplinary 
panel of neurosurgeons, radiation oncologists and neuro-oncologists. The patient should be informed 
about the treatment alternatives and the pros and cons of the options should be presented in an 
unbiased way so as to allow the patient an informed decision about the choice of treatment. 
 
Surgery  
Surgery is the treatment of choice for the majority of symptomatic and enlarging meningiomas, serving 
the dual role of relieving symptoms and mass effect and providing tissue for distinguishing histological 
type and WHO grade of malignancy (evidence level II, recommendation level B). Surgical risks should 
be fully discussed with the patients prior to surgery including location-specific risks. There is no 
evidence that prophylactic antiepileptic drugs (AEDs) reduce the incidence of peri- or post-operative 
epilepsy. However, certain locations are more prone to seizures e.g. frontal, temporal, and parietal 
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meningiomas have a higher risk than occipital tumors, and convexity and parasagittal/falx 
meningiomas have a higher risk than tumors of the skull base37-39. 
Careful pre-operative planning reduces the risk of post-operative deficits. Attention to venous anatomy 
is a key factor in successful surgery, particularly for meningiomas involving the venous sinuses. While 
it is generally safe to divide the anterior third of the sagittal sinus, inadvertent damage to cortical veins 
and intra-diploic venous drainage can lead to post-operative venous infarction with devastating 
consequences. Image guidance is now routinely used to position the craniotomy and allows image 
fusion of multiple data sets that provide information about critical neurovascular structures. 
Meningiomas that involve the skull base may result in holes in the frontal, sphenoid and ethmoid air 
sinuses - these holes must be sealed off to prevent post-operative cerebrospinal fluid leaks. Care 
should also be taken when resecting meningiomas near to the optic apparatus so as not to disrupt 
blood supply which could result in visual loss. Intra-operative neurophysiological monitoring, e.g. facial 
nerve and brainstem-evoked potentials, may help to minimize neurological deficits. 
The general principles of meningioma surgery are dividing the tumor from its blood supply and internal 
debulking followed by peripheral dissection. The aim is gross total resection including involved dura 
and bone, but this is determined by tumor location and size. If tumor location does not permit complete 
resection without significant neurological deficit, maximum safe resection has to be defined as primary 
surgical goal. If tumor remnants need to be left, these can be monitored with MRI or treated with post-
operative conformal or stereotactic fractionated radiotherapy or radiosurgery, depending on location, 
size and proximity to critical structures, e.g., cavernous sinus. 
Extent of resection (EOR) as idefined by the Simpson Grade (see table 4, main text)  is an important 
prognostic factor for risk of tumor recurrence40. Even though the relevance and prognostic strength of 
the Simpson classification has been questioned41, a recent series shows that it still has a role in 
assessing the risk of recurrence 40. Today, the intraoperative assessment of Simpson grade should be 
confirmed by postoperative MRI that can be performed within 48 h after surgery or after 3 months to 
avoid artifacts. In case of incomplete resection or suspected WHO grade II or III meningioma, early 
MRI within 48 hours should be performed to plan further therapy. In modern neurosurgery, the 
potential benefit of radical surgical resection must be balanced against the risks of complications and 
causing neurological deficit. In WHO grade I meningioma, defining EOR as either gross total resection, 
i.e. no residual solid tumor, or subtotal resection (STR) is an equally good prognostic factor for tumor 
recurrence41. Several clinical research consortia including the European Organization for Research 
and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) have adopted 
these definitions for use in prospective clinical trials42. 
Regarding spinal meningiomas, the majority of data supports surgical strategies striving for 
completeness of excision. Recurrence rates of spinal meningiomas after surgical resection have been 
reported in the range of 1.·3 – 14.·7%43-46. There is consensus that incomplete resection is a risk 
factor for recurrence but it is unclear whether Simpson grade I resection achieves better long-term 
outcome than Simpson grade II resection43,46-48. Most papers report lower recurrence rates after 
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resection of the involved dura but at the cost of a higher complication rate, particularly for 
meningiomas located unfavorably or with prominent calcification45. Therefore, Simpson grade I 
resection should be aimed for in all cases of spinal meningioma with a favorable location, but only if 
this can be achieved without compromising neurological function and if a safe and uncomplicated 
dural repair is feasible. For patients with ventrally located meningiomas or with calcified dural 
attachment, excision of the dura should not be the goal – coagulation of the dural attachment is 
sufficient.  
In conclusion, the decision for surgery versus observation should balance the benefit of surgery, i.e. 
tumor removal versus potential  long-term sequelae of the surgical treatment34.  
 
Radiotherapy 
External beam radiation therapy (RT) has been used extensively in patients with meningioma for the 
following indications: (i) in tumor locations not amenable to surgery, (ii) in tumors that are not 
completely resected, (iii) in atypical and malignant tumors and (iv) in recurrent tumors. No randomized 
or prospectively controlled studies have evaluated tumor control and survival after conventional RT. 
Nevertheless, retrospective studies of patients with residual or recurrent WHO grade I meningiomas 
report a local control rate of 75-90% at 10 years49-53. In a series of 82 patients with skull base 
meningiomas treated with conventional RT, Nutting et al. reported 5-year and 10-year local tumor 
control rates of 92% and 83%, respectively52. In another series of 101 patients treated with 3-
dimensional (3D) conformal RT, Mendenhall et al. reported local control of 95% at 5 years and 92% at 
10 and 15 years, respectively, and cause-specific survival rates of 97% and 92%, respectively51. The 
reported control and survival after subtotal resection and RT are similar to those observed after 
complete resection, and better than that achieved with incomplete resection alone54,55 (evidence level 
III, recommendation level B). 
Large skull base meningiomas may present a therapeutic challenge. Also in these tumors, RT has 
been suggested as an effective treatment. A 5-year tumor control in the range of 90 to 97% has been 
reported for skull base meningiomas up to 5 cm in greatest dimension53,56,57; however, meningiomas 
larger than 5 cm in size seem to be associated with worse local control58,59. There is little evidence that 
timing of RT is important, as local control and survival rates are similar whether the treatment is given 
as a part of the primary treatment or at the time of recurrence51-53,60. In most series, the administered 
dose ranged between 50 and 57 Gy delivered in daily fractions of 1.8-2 Gy. The tumor control rates 
were similar for doses of 50-55 Gy or > 55 Gy51,53,57,59-64. Doses below 50 Gy were associated with 
higher, mostly local recurrence rates51,60.  
There is a significant long-term risk of cognitive impairment after RT to the brain65. In order to spare 
tumor-surrounding sensitive neurovascular structures, technical advances have enabled 
administration of fractionated RT by the use of intensity modulated radiation therapy (IMRT) and 
fractionated stereotactic radiotherapy (FSRT). FSRT has shown to improve symptoms within 1-3 
months after treatment66. Using FSRT with median doses of 57 Gy, Milker-Zabel et al. reported a 10-
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year local control of 89% in 317 patients with either skull base or intracranial meningiomas, and similar 
tumor control rates have been observed in other series of FSRT59,62,67,68. Combs et al. evaluated the 
outcomes of 506 patients with skull base meningiomas who received FSRT (n =376) or IMRT (n=131), 
reporting a similar local control of 91% at 10 years for patients with WHO grade I meningiomas67. 
Thus, both techniques are probably effective as primary and salvage treatment for meningiomas, with 
a local control at 5 and 10 years similar to that reported with conformal RT. Particle therapies like 
proton and carbon ion irradiation allow a high dose deposition on the tumor providing very low doses 
to the surrounding adjacent tissues via the “Bragg Peak”. Irradiation and re-irradiation of meningioma 
using protons or carbon ions as stand-alone therapies or in combination with photon therapy have 
been reported to be well tolerated and to allow dose escalation, particularly in WHO grade II and III 
meningioma, showing good local control rates61,69-71. There is some evidence that dose escalation >60 
Gy or even 65 Gy could lead to a better cause specific survival in patients with atypical and malignant 
meningioma69. However, proton therapy remains to be evaluated in prospective clinical trials. 
The role of RT for WHO grade II meningiomas, specifically its timing, remains unclear. In a series of 
83 patients of whom 66% had undergone GTR, Park et al. reported a 5-year tumor control of 59% 
versus 44% with and without postoperative RT72. Improved progression-free survival rates after 
postoperative RT have been observed in comparative retrospective series73-75. On the contrary, other 
studies showed no advantages in terms of progression-free survival for adjuvant RT76-78. For WHO 
grade III meningiomas, postoperative RT using doses of 55-60 Gy in 1.8-2.0 Gy daily fractions is an 
established treatment by consensus. There is a trend toward longer survival for patients who had 
received adjuvant RT after surgery compared to those treated with surgery alone79,80. 
Current clinical trials address the question of dose: In the RTOG 0539 trial, "intermediate risk" 
meningiomas (i.e. recurrent WHO grade I or WHO grade II after GTR) are treated by RT with 54 Gy in 
30 fractions after GTR, while “high risk meningioma” (i.e. WHO grade II recurrent disease, WHO grade 
II after STR and all WHO grade III) receive up to 60 Gy (NCT00895622). The EORTC 22042–26042 
trial evaluated the efficacy of high-dose radiotherapy (RT) in atypical/malignant meningioma 
(NCT00626730). In this phase II study, WHO grade II and grade III tumors post GTR are irradiated 
with 60 Gy in 30 fractions. After STR, 60 Gy plus a 10 Gy boost on the remaining tumor volume are 
delivered. The ROAM / EORTC 1308 trial (ISRCTN71502099) is a multicenter, phase III, randomized 
controlled trial that is currently recruiting patients and will answer the question whether early adjuvant 
RT reduces recurrence compared with active monitoring in patients, who have undergone GTR of 
newly diagnosed atypical meningioma. ?81. 
Radiosurgery  
In cases that are associated with increased surgical risk, radiosurgery by gamma knife, cyber knife or 
other types of linear accelerator can be regarded as an effective alternative for radiologically 
diagnosed meningiomas. The dose used for radiosurgery in meningiomas is highly dependent upon 
the technique applied, the prescribed isodose, the proximity of neurovascular structures at risk, as well 
as the size and configuration of the tumor. Generally, a single coverage dose of 14 to 16 Gy is 
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recommended 77. Besides direct cellular and toxic effects on tumor cells, the impact of a single high 
dose irradiation on nutritive microvessels seems to be relevant82. Radiosurgery may be indicated – 
even as first therapeutic option - in particular situations like tumor location in the cavernous sinus or 
the clivus, multiple meningiomas, partially resected tumors, recurrent meningioma, or in cases where 
comorbidities preclude open surgery. In these situations, radiosurgery can be used as an exclusive 
therapeutic option based on neuroimaging alone or as part of a combination therapy together with a 
planned partial surgical resection. A series of 35 retrospective studies showed 5 year progression free 
survival (PFS) of 86-100 percent after primary radiosurgery83. A study analyzing the outcome of 79 
patients with cavernous sinus meningiomas treated by radiosurgery alone revealed a tumor control 
rate of 89.8% at 10 years84. A similar excellent clinical outcome and low toxicity have been reported in 
a few series with the use of multi-session radiosurgery at doses of 18-25 Gy delivered in 2 to 5 daily 
fractions in patients with meningiomas larger than 2.·5-3.·0 cm in size and/or situated close to critical 
structures85,86. Although promising, the limited numbers of patients and follow-up time does not allow 
drawing definitive conclusions on the use of hypofractionated regimens in routine clinical practice as 
an alternative to conventionally fractionated RT. Petroclival meningiomas or sphenoid meningiomas 
are potential candidates for treatment strategies combining surgery and radiosurgery49,87. In the latter 
tumors, combination therapy allows surgical decompression of the optic apparatus and irradiation of 
tumor remnants in the cavernous sinus. Radiosurgery has also been selected for treatment of 
recurrent atypical meningiomas. The overall survival of these patients was 87% after 5 years and 75% 
after 10 years88. Multiple meningiomas and intracranial meningiomatosis might be an indication for 
radiosurgery, if there is no more treatment potential for surgery or fractionated RT89.  
There are no prospective randomized data comparing fractionated RT and radiosurgery. The control 
rates 5 and 10 years after RT or radiosurgery for WHO grade I meningiomas are very similar. Ten year 
PFS after RT using FSRT or IMRT was reported as 91% whereas 83 to 97% are documented for 
radiosurgery67,90. Radiosurgery allows treatment of a circumscribed volume using a single dose, 
therefore achieving a high patient comfort. On the other hand, the use of radiosurgery is limited to 
small and non-infiltrative disease and locations distant from sensitive critical structures such as visual 
pathways because of the radiosensitivity of late reacting normal tissue to dose per fraction. In these 
indications, fractionated RT that sometimes can be performed using the same machines is preferred to 
radiosurgery. In case of infiltrative meningioma growth or WHO grade II or III meningiomas, which 
have a high recurrence rate, fractionated techniques seem superior91. 
Any decision for RT should take into account the long-term side effects of RT, and these should be 
discussed with the patient. The incidence of treatment toxicity ranges from 3.4% to 16.7%. 
Neurocognitive impairment has been described in 53% of cases65   Although blindness due to 
involvement of the neuro-optic structures into the treatment field has been reported to occur in 5% of 
patients, newer studies show this risk to be significantly lower, probably due to the modern treatment 
techniques and doses92,93. If the pituitary gland receives irradiation, there may be changes in hormonal 
levels; although hypogonadism is relatively rare (up to 6%), hypopituitarism is reported in up to 50% of 
cases, and early involvement of the endocrinologist is advisable92. 
Kommentiert [RG1]: Reference Douw fehlt immer noch!!! 
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Peptide Receptor Radionuclide Therapy (PRRT) 
Some meningiomas show prominent expression of somatostatin receptors and peptide receptor 
radionuclide therapy (PRRT) using radiopeptides targeting somatostatin receptors such as 90Y-
DOTATOC ([90Y-DOTA0, Tyr3]-octreotide), 177Lu-DOTATATE ([177Lu-DOTA0,Tyr3]-octreotate) and 
111ln-Pentreotide has been evaluated in small series or singular cases of somatostatin receptor-
positive meningiomas. PRRT was well tolerated and some disease stabilizations and few partial 
responses were reported. However, the available evidence is anecdotal and well designed studies are 
needed to evaluate the role of PRRT in meningiomas. In the meantime, PRRT should preferentially be 
offered in the framework of clinical studies94-98. 
Embolization 
Preoperative embolisation of meningiomas aims at reducing blood loss during surgical resection99-
101.Indications for embolisation of meningiomas vary substantially depending on the neurosurgical 
team102. There is no controlled study that shows better clinical outcomes of surgery if preceded by pre-
operative embolisation. Consequently, there is no general indication for embolisation of meningioma; 
individual indications are assessed on a case by case basis by each team. The principle is to first and 
foremost occlude the afferent arteries that cannot be reached by the surgeon when accessing the 
tumor. This is performed by free flow particle injection or coil embolisation within 24 hours of planned 
surgery. Complications may arise when the neuroradiologist tries to distally guide the embolus into the 
capillary bed of the tumor. This can result in tumor hemorrhage, erratic embolisation through 
anastomosis or cranial nerves palsy103,104. Four different anatomical scenarios can be discussed: (i) In 
the very common convexity meningiomas, there is infrequently an indication for preoperative 
embolisation. If an embolisation is indicated, 100 to 300 µm particles are injected into the middle 
meningeal artery. These small particles allow a more distal penetration into the tumor bed. This results 
in a more substantial necrotic effect on the tumor, but their use also entails a higher risk of intra-
tumoral hemorrhage103,105. A controlled study indicated that preoperative embolisation resulted in a 
significant reduction of perioperative blood loss99. Reported complications are tumor hemorrhage and 
ischemia due to erratic movement of the emboli. The incidence of complications varies from 0 to 9 %. 
(ii) Olfactory meningiomas are generally vascularized by ethmoidal arteries. Since these are branches 
of the ophthalmic artery implicating a risk of jeopardizing vision by embolisation, these tumors should 
never be embolized. (iii) Meningiomas of the cavernous sinus can be subjected to preoperative 
embolisation. However, the afferent arteries are small-sized dural arteries emanating from the carotid 
siphon which, aside from rare cases, are not amenable to selective catherization. Therefore, if an 
indication for embolisation of a cavernous sinus meningioma is made in very rare cases due to a lack 
of therapeutic alternatives, the internal carotid artery would need to be occluded after testing patency 
of the Circle of Willis. (iv) Petroclival meningiomas can be embolised via the meningeal trunk of the 
ascending pharyngeal artery. This artery cannot be controlled surgically during lateral approaches to 
the clivus, the petrous bone or the cerebellopontine angle106. 
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Pharmacotherapy and experimental therapies 
 
Pharmacotherapy of meningiomas is typically considered in the following main patient populations: (i) 
patients with recurrent or progressive meningiomas of all tumor grades in whom surgical resection or 
RT are no longer feasible, and (ii) patients with metastatic meningioma. Principally, systemic therapy 
appears to be able to inhibit meningioma growth to some extent107. A variety of drugs have been 
studied in meningiomas. However, the interpretation of most of the available studies is limited by 
several factors, in particular small patient numbers, the retrospective design of most studies, the 
heterogeneity of patient populations with regard to tumor type and prior therapies, the lack of 
comparator treatment arms or reliable historical benchmark activity parameters and the lack of 
standardized response criteria. Thus, pharmacotherapy of meningioma has so far an unclear benefit 
and has to be considered experimental. Overall, inclusion of patients with meningiomas in clinical trials 
evaluating novel treatment approaches is recommended. Depending on ongoing molecular 
classification of meningiomas, targeted therapies are evolving (see Table 3, main text) . 
 
WHO grade I meningiomas 
Hydroxyurea, temozolomide, irinotecan, interferon-alpha, sandostatin LAR, pasireotide LAR, imatinib, 
erlotinib and gefitinib have been studied in retrospective and single-arm phase II studies in WHO 
grade I meningiomas that have failed surgical resection and radiotherapy108,109. Mifepristone was 
studied in a randomized phase III trial but failed to show an advantage over placebo110. The PFS-6 
rates in these studies ranged from 0% to 67%, while median OS times were only inconsistently 
reported and ranged from 7 to 13 months108. The lack of clear data on the natural course and the 
uncontrolled character of these studies preclude definite conclusions. Based on the available data, 
none of the evaluated drugs showed clear signs of clinically relevant activity sufficient to recommend 
them for standard practive clinical use. Notably, temozolomide is not active in meningioma111. 
 
WHO grade II and III meningiomas 
Retrospective studies and small prospective studies have evaluated a range of drugs including 
hydroxyurea, cycophosphamide/adriamycin/vincristine chemotherapy, interferon-alpha, megestrol 
acetate, medroxy-progesterone acetate, octreotide, sandostatin LAR, pasireotide LAR, imatinib, 
erlotinib, gefitinib, vatalanib, sunitinib and bavacizumab in patients with WHO grade II and III 
meningiomas108. PFS-6 rates ranged from 0% to 64% and median OS times from 6 to 33 months in 
patients progressing after surgical resection and radiotherapy108. The most promising results have 
been reported for bevacizumab, vatalanib and sunitinib, all drugs with anti-angiogenic 
properties107,108,112-114. These results need to be confirmed in prospective controlled trials, before 
clinical use of these compounds in patients with WHO grade II and III meningiomas can be 
recommended. An ongoing EORTC phase II trial (NCT02234050) explores the efficacy of trabectedin, 
a tetrahydroisoquinoline that has shown promising activity in recurrent WHO grade II and grade III 
meningiomas115. 
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Surveillance and follow up of meningiomas 
 
There is only litte  data available on the best follow-up schedule for meningiomasTherefore, the 
following recommendations are based more on expert consensus opinion rather than evidence. 
An experienced neurosurgeon or neurooncologist should be in charge for the follow- up.. This must be 
accompanied in special cases by additional specialists, e.g., an ophthalmologist should closely 
monitor the visual status in case of a tuberculum sellae meningioma or an audiologist should monitor 
the hearing level in case of a cerebellopontine angle tumor. The  follow -up intervals  should depend 
not only from resection status, size and location of the tumor, but also age and the general and 
neurological status of the patient.  
For small, asymptomatic meningiomas we suggest MRI with contrast medium 6 months after 
diagnosis and then annually, as long as the patient remains asymptomatic. After five years this interval 
can be doubled. In patients where the identification of tumor progression has no clinical relevance or 
consequense, e.g. patients with limited life expectancy due to high age or severe co-morbidities, 
controls may be omitted.. 
 
Monitoring after initial treatment should depend on the extent of resection and grading of the tumor. 
Even for WHO I meningiomas resected totally, the 10-year recurrence rate is reported up to 39% and 
thus more common than previously thought. The EOR should be controlled with a baseline MRI either 
within 48 hours after the operation or after 3 months. Thereafter, we suggest annual MRI controls for 
the first five years and then biannually. 
If resection is known to be incomplete, EOR should be documented by early postoperative MRI within 
48 hours. For WHO grade I tumors after STR, the 10-year progression rates vary between 55 and 
100% suggesting a more vigilant long-term follow-up116,117. For those cases, MRI at 6 and 12 months 
is recommended, then annually.  
The course of patients with WHO grade II meningiomas might vary within a wide range. The 5-year 
recurrence/progression rates are reported  as 30% and 40% after GTR and STR, respectively73,76. To 
monitor these tumors, we suggest an early postoperative MRI within 48 hours as a basis for further 
observation. Follow-up MRI should be done every 6 months for 5 years, then annually. 
WHO grade III meningiomas are aggressive tumors with very poor local control, even after multimodal 
treatment. In the recent studies utilizing the WHO 2007 grading scheme, the 5-year-PFS ranged from 
12 to 57%, even after resection and RT. For these tumors very close follow-up is recommended118. 
After the initial, early post-treatment MRI, cranial imaging should be routinely done every 6 months, in 
rapidly growing cases every 3 months.  
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